/daily ·13 JUL 2026 ·MONDAY ·3 MIN READ ·7 STORIES

Lecanemab under the skin

The Alzheimer's Association International Conference delivered the week's biggest longevity-adjacent clinical headline: a self-injected Alzheimer's drug that matches the efficacy of the IV drip.

01 / The Day

MONDAY 13 JUL 2026, ranked

Subcutaneous lecanemab matches IV efficacy in early Alzheimer's data

Data presented at AAIC 2026 shows that a patient-administered autoinjector formulation of lecanemab (Leqembi) produced equivalent drug exposure, amyloid plaque clearance, and safety outcomes to intravenous infusion in early Alzheimer's patients — enabling home treatment without scheduled clinic visits.

Why it mattersConverting a hospital-infusion therapy to a home injection is among the most reliable mechanisms for expanding patient reach; Alzheimer's is neither rare nor short in duration.

01 aaic.alz.org↗

Nature Medicine review maps the state and limits of biological aging clocks

A review by Tony Wyss-Coray and Eric Topol in Nature Medicine synthesizes progress across methylation, proteomic, transcriptomic, and organ-specific aging clocks, assessing their predictive value for disease risk and their measured responsiveness to lifestyle and pharmacological interventions.

Why it mattersThe field's two most cited researchers publishing a joint calibration review signals that the clock literature is mature enough for a critical audit; their conclusions will steer the next funding cycle.

02 doi.org↗

Centenarian SIRT6 gene variants suppress cellular senescence via DNA repair

Specific SIRT6 variants enriched in centenarians were shown to resist cellular senescence by enhancing DNA repair machinery and suppressing transposable element expression, producing a measurably lower senescent cell burden. AAV delivery of the variant and fucoidan treatment both reproduced aspects of the effect in experimental models.

Why it mattersA genetically validated longevity variant that can be delivered therapeutically is a rare alignment of biological plausibility and a tractable translational pathway.

03 fightaging.org↗

Impaired glymphatic drainage detected in early-stage Parkinson's disease

MRI studies of patients in early Parkinson's disease identified elevated cerebrospinal fluid stasis consistent with impaired glymphatic drainage — the brain's waste-clearing system — suggesting this dysfunction may precede and accelerate the neurodegeneration characteristic of synucleinopathies.

Why it mattersPre-symptomatic glymphatic failure would make it a plausible intervention target before substantial neuronal loss, shifting the therapeutic window earlier in disease course.

04 fightaging.org↗

BCG vaccination reduced amyloid-beta and activated brain immunity in healthy adults

A study found that BCG vaccination induced persistent trained immunity in cerebrospinal fluid, with compartment-specific immune changes and decreased amyloid-beta levels in cognitively normal participants — adding experimental weight to the case for a century-old tuberculosis vaccine as a potential Alzheimer's preventive.

Why it mattersBCG is cheap, widely available, and has extensive safety data — an unusually low barrier to acting on any validated neuroprotective signal.

05 fightaging.org↗

Multimodal lifestyle trial slows methylation aging clock by 2.2 percent

A randomized trial combining structured exercise with Bifidobacterium-containing yogurt decelerated the Dunedin pace-of-aging methylation clock by 2.2% in participants — one of the few human trials to demonstrate a measurable aging-clock response to an active intervention rather than to disease progression.

Why it mattersEvidence that a methylation aging clock responds to a controlled intervention validates it as a trial endpoint rather than merely a correlational biomarker, which changes how future studies are designed.

06 fightaging.org↗

Longevity-linked BPIFB4 variant curbs inflammation through platelet CD47

Researchers found that a BPIFB4 gene variant enriched in long-lived individuals enhances immune regulation via platelet CD47 upregulation, dampening systemic inflammation. A recombinant version of the protein reproduces the effect in experimental models, pointing toward a deliverable therapeutic candidate.

Why it mattersA longevity-associated protein that acts through a known receptor and can be administered as a recombinant compound offers a more direct path to clinical use than gene-level interventions.

07 fightaging.org↗

Be subscriber #012 the weekly ten, every friday by email · no spam · unsubscribe anytime

Past days

The Daily Archive

/FRI 31 JULBlood proteins predict liver disease 16 years early /WED 29 JULWednesday, 29 July — Clocks, guts, heat /MON 27 JULFDA Splits the Peptide Vote, Salk Finds Zombie Cells' Weakness, and GBD Says Healthy Years Aren't Keeping Pace /FRI 24 JULThe Drug That Lost Its Heart /WED 22 JULBlood, bone, and the morbidity gap /FRI 17 JULFriday in Longevity: Clocks, Fat, and Immune Decay /WED 15 JULSenescent terrain /MON 13 JULLecanemab under the skin /FRI 10 JULLongevity | Jul 10 2026: Gut, Senescence, Epigenetics /WED 08 JULDrugs remapped to aging hallmarks, ovarian aging reversed, and a 50% molecular gap /MON 06 JULCentenarian chemistry, sleeping circuits, and reprogrammed eyes /FRI 03 JULOvaries, progenitors, and oxygen /WED 01 JULTelomere signals, proteomic clocks, and faster biological aging /MON 29 JUNMonday, June 29 — Longevity /FRI 26 JUNWhen you sleep matters; what your cells do with miscopied RNA also matters /TUE 23 JUNGenes, Clocks, and GLP-1s /MON 22 JUNMonday: Senescent cells, climbing clocks, and late-life gene therapy /FRI 19 JUNLongevity — June 19, 2026 /WED 17 JUNClocks, Loops, and One Very Productive Bacteria /MON 15 JUNReprogramming closes first human trial; circadian link firms /FRI 12 JUNAging regimes, borrowed sleep, and a race to measure biological age